MND in the news - CuATSM (copper ATSM)
Australian media has recently reported on a poster presented at the 29th International Symposium on ALS/MND held in Glasgow in December that reported outcomes of a phase 1 Clinical Trial conducted in Australia. The phase 1 trial was designed to test the safety and dosage of the compound CuATSM and research funds donated to MND NSW have been part of the $1.2million invested in trials of copper ATSM through the MND Research Institute of Australia.